NYSEARCA:RNN -
The current stock price of RNN is 5.24 null. In the past month the price decreased by -10.27%. In the past year, price decreased by -76.52%.
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
REXAHN PHARMACEUTICALS INC
15245 SHADY GROVE ROAD SUITE 455
ROCKVILLE MD 20850
CEO: Douglas J. Swirsky
Phone: 240-268-5300
The current stock price of RNN is 5.24 null. The price increased by 0.19% in the last trading session.
The exchange symbol of REXAHN PHARMACEUTICALS INC is RNN and it is listed on the NYSE Arca exchange.
RNN stock is listed on the NYSE Arca exchange.
REXAHN PHARMACEUTICALS INC (RNN) has a market capitalization of 21.06M null. This makes RNN a Nano Cap stock.
REXAHN PHARMACEUTICALS INC (RNN) has a support level at 4.82 and a resistance level at 5.38. Check the full technical report for a detailed analysis of RNN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RNN does not pay a dividend.
REXAHN PHARMACEUTICALS INC (RNN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.53).
ChartMill assigns a fundamental rating of 2 / 10 to RNN. RNN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RNN reported a non-GAAP Earnings per Share(EPS) of -3.53. The EPS decreased by -498.31% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -75.35% | ||
ROE | -91.82% | ||
Debt/Equity | 0.01 |